Iranian Journal of Medical Sciences

Document Type : Original Article(s)

Authors

1 Department of Cell and Molecular Biology, Faculty of Biological Science, University of Isfahan, Isfahan, Iran

2 Department of Animal Sciences, Faculty of Agriculture, Yasuj University, Iran

3 Department of Genetics, Department of Obstetrics, Gynecology, and Reproductive Sciences, and Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA

10.30476/ijms.2024.103243.3647

Abstract

Background: An incapacitating chronic inflammatory neurodegenerative illness, known as multiple sclerosis (MS), is characterized by lymphocyte infiltration into the central nervous system. We aimed to identify specific miRNAs whose altered expression correlates with MS diagnosis and therapy selection, which could be biomarkers for these aspects of the disease.
Methods: The GSE21079 dataset was obtained for this study using Geoquery version 2.50.5 from the Gene Expression Omnibus database. The miRNAs exhibiting the highest variance were selected, and a miRNA-miRNA interaction network was constructed through a Bayesian network utilizing the bnlearn R package (version 4.7.1). The adjacency matrix generated from the learned network was subsequently analyzed in the Cytoscape environment. For the workbench lab, whole blood samples were collected from the MS Research Center and Al-Zahra Hospital in Isfahan, Iran, between June 2019 and October 2019. RNA extraction was conducted in the laboratory at Isfahan University. Real-time PCR (RT-PCR) was employed to validate the expression changes of the candidate mirRNAs (hsa-miR-520d-3p, hsa-miR-449a). The results were analyzed using REST 2009 software.
Results: The Notch1 signaling pathway was targeted by hsa-miR-520d-3p and hsa-miR-449a in MS patients, which led to downregulation of critical genes, such as LIM and SH3 protein 1 (LASP1), Tubulin Alpha1c (TUBA1C), and S100 calcium binding protein A6 (S100A6). Furthermore, the results from RT-PCR among 50 whole blood samples, comprising 30 cases of MS and 20 control cases, indicated that the expression levels of miRNA in patients with MS exhibited a statistically significant difference compared to those in healthy individuals, with values of 0.324 for hsa-miR-520d-3p and 0.075 for hsa-miR-449a. These values correspond to a downregulation of 3.1-fold and 13.3-fold, respectively.
Conclusion: The findings indicate that MS patients have lower expression levels of hsa-miR-520d-3p and hsa-miR-449a. 

Highlights

Nafiseh Karimi (Google Scholar)

Majid Motovali Bashi (Google Scholar)

Keywords

  1. Shang Y, Smith S, Hu X. Role of Notch signaling in regulating innate immunity and inflammation in health and disease. Protein Cell. 2016;7:159-74. doi: 10.1007/s13238-016-0250-0. PubMed PMID: 26936847; PubMed Central PMCID: PMCPMC4791423.
  2. Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4:43. doi: 10.1038/s41572-018-0041-4. PubMed PMID: 30410033.
  3. Alamshah N, Sari S, Mirfakhraie R. Association Study of miR-23a rs3745453 Polymorphism with Multiple Sclerosis in a Sample of Iranian Population. New Cellular and Molecular Biotechnology Journal. 2017;7:90-8.
  4. International Multiple Sclerosis Genetics C. A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. Nat Commun. 2019;10:2236. doi: 10.1038/s41467-019-09773-y. PubMed PMID: 31110181; PubMed Central PMCID: PMCPMC6527683.
  5. Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D, et al. miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells. 2020;9. doi: 10.3390/cells9020276. PubMed PMID: 31979244; PubMed Central PMCID: PMCPMC7072450.
  6. Safari-Alighiarloo N, Rezaei-Tavirani M, Taghizadeh M, Tabatabaei SM, Namaki S. Network-based analysis of differentially expressed genes in cerebrospinal fluid (CSF) and blood reveals new candidate genes for multiple sclerosis. PeerJ. 2016;4:e2775. doi: 10.7717/peerj.2775. PubMed PMID: 28028462; PubMed Central PMCID: PMCPMC5183126.
  7. Ho DM, Artavanis-Tsakonas S, Louvi A. The Notch pathway in CNS homeostasis and neurodegeneration. Wiley Interdiscip Rev Dev Biol. 2020;9:e358. doi: 10.1002/wdev.358. PubMed PMID: 31502763.
  8. Hou Y, Feng F, Yang R. Effect of miR449amediated Notch signaling pathway on the proliferation, apoptosis and invasion of papillary thyroid carcinoma cells. Oncol Rep. 2020;43:471-80. doi: 10.3892/or.2019.7443. PubMed PMID: 31894345; PubMed Central PMCID: PMCPMC6967094.
  9. Karimi N, Motovali-Bashi M, Ghaderi-Zefrehei M. Gene network reveals LASP1, TUBA1C, and S100A6 are likely playing regulatory roles in multiple sclerosis. Front Neurol. 2023;14:1090631. doi: 10.3389/fneur.2023.1090631. PubMed PMID: 36970516; PubMed Central PMCID: PMCPMC10035600.
  10. Trotta E. On the normalization of the minimum free energy of RNAs by sequence length. PLoS One. 2014;9:e113380. doi: 10.1371/journal.pone.0113380. PubMed PMID: 25405875; PubMed Central PMCID: PMCPMC4236180.
  11. Karimi N, Motovali-Bashi M, Ghaderi-Zefrehei M. Gene network reveals LASP1, TUBA1C, and S100A6 are likely playing regulatory roles in multiple sclerosis. Front Neurol. 2023;14:1090631. doi: 10.3389/fneur.2023.1090631. PubMed PMID: 36970516; PubMed Central PMCID: PMCPMC10035600.
  12. Ma X, Zhou J, Zhong Y, Jiang L, Mu P, Li Y, et al. Expression, regulation and function of microRNAs in multiple sclerosis. Int J Med Sci. 2014;11:810-8. doi: 10.7150/ijms.8647. PubMed PMID: 24936144; PubMed Central PMCID: PMCPMC4057480.
  13. Cao L, Chen Y, Zhang M, Xu DQ, Liu Y, Liu T, et al. Identification of hub genes and potential molecular mechanisms in gastric cancer by integrated bioinformatics analysis. PeerJ. 2018;6:e5180. doi: 10.7717/peerj.5180. PubMed PMID: 30002985; PubMed Central PMCID: PMCPMC6033081.
  14. Giaimo BD, Oswald F, Borggrefe T. Dynamic chromatin regulation at Notch target genes. Transcription. 2017;8:61-6. doi: 10.1080/21541264.2016.1265702. PubMed PMID: 28027012; PubMed Central PMCID: PMCPMC5279717.
  15. Sun Y, Ji J, Zha Z, Zhao H, Xue B, Jin L, et al. Effect and Mechanism of Catalpol on Remyelination via Regulation of the NOTCH1 Signaling Pathway. Front Pharmacol. 2021;12:628209. doi: 10.3389/fphar.2021.628209. PubMed PMID: 33708131; PubMed Central PMCID: PMCPMC7940842.
  16. Wu T, Chen G. miRNAs Participate in MS Pathological Processes and Its Therapeutic Response. Mediators Inflamm. 2016;2016:4578230. doi: 10.1155/2016/4578230. PubMed PMID: 27073296; PubMed Central PMCID: PMCPMC4814683.
  17. Ouspid E, Razazian N, Moghadasi AN, Moradian N, Afshari D, Bostani A, et al. Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran. Neurosciences (Riyadh). 2018;23:129-34. doi: 10.17712/nsj.2018.2.20170434. PubMed PMID: 29664454; PubMed Central PMCID: PMCPMC8015441.
  18. Freiesleben S, Hecker M, Zettl UK, Fuellen G, Taher L. Analysis of microRNA and Gene Expression Profiles in Multiple Sclerosis: Integrating Interaction Data to Uncover Regulatory Mechanisms. Sci Rep. 2016;6:34512. doi: 10.1038/srep34512. PubMed PMID: 27694855; PubMed Central PMCID: PMCPMC5046091.